Vivos Therapeutics Announces Material Debt Reduction
Vivos Therapeutics exchanged $2,861,270 of outstanding principal under its Streeterville Note for 11,445,080 common shares at $0.25 per share through twelve exchange agreements dated August 31, 2026. Combined with an August 4 exchange of $3,250,000 of principal for Series B preferred stock and 1,812,031 common shares, the note balance has fallen to approximately $3.7 million from the original $8,225,000 issued June 9, 2025.
Key figures
- Shares issued
- 11445080
- Principal exchanged
- 2861270
- Remaining note balance
- $3.7 million
- Original note principal
- 8225000
- Exchange price per share
- 0.25
- Prior exchange principal
- 3250000
- Prior exchange common shares
- 1812031
- Prior exchange preferred shares
- 2500
- Implied reduction from original principal
- approximately $4.5 million
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.